Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

NCT04579380 is registered in ClinicalTrials.gov with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT04579380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04579380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 11, 2021
Completion date
December 31, 2026
Enrollment
217 (actual)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract neoplasms, carcinoma, non-small-cell lung, her2 mutations breast neoplasms, urologic neoplasms, uterine cervical neoplasms, uterine neoplasms